US2021386819A1PendingUtilityA1

Bioengineered lactobacillus probiotics and the uses thereof

Assignee: PURDUE RESEARCH FOUNDATIONPriority: Jul 2, 2018Filed: Aug 13, 2021Published: Dec 16, 2021
Est. expiryJul 2, 2038(~11.9 yrs left)· nominal 20-yr term from priority
A61K 2035/115A61K 35/747A23K 10/18A61P 31/04A61K 2039/552A61K 35/741A61K 9/19A61P 37/06A61K 38/164A23L 33/135A23Y 2220/63A23Y 2220/17A61K 9/0056A23V 2400/125A23V 2400/165
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

In some illustrative embodiments, the present disclosure relates to a method for treating or preventing an inflammatory condition of a patient comprising the step of administering a therapeutically effective amount of Next Generation Bioengineered Probiotics (NGBP), together with one or more pharmaceutically acceptable carriers, diluents, and excipients, to the patient in need of relief from said inflammatory condition. In some other embodiments, the present application relates to an animal feed supplement for improving animal health and meat production compromising Next Generation Bioengineered Probiotics (NGBP). Yet in some other embodiments, the present invention relates to method for improving animal health and/or meat production comprising the step of adding an effective amount of Next Generation Bioengineered Probiotics (NGBP) to the feed of said animal.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating or preventing an inflammatory condition of a patient comprising the step of administering a therapeutically effective amount of Next Generation Bioengineered Probiotics (NGBP), together with one or more pharmaceutically acceptable carriers, diluents, and excipients, to the patient in need of relief from said inflammatory condition, wherein said NGBP is a bioengineered  Lactobacillus casei  ( L. casei ) Probiotic (BLP) overexpressing a polypeptide having the sequence of SEQ ID NO:1 or SEQ ID NO: 2. 
     
     
         2 . The method of  claim 1 , wherein said inflammatory condition comprises Crohn's disease (CD), inflammatory Bowel Disease (IBD), and ulcerative colitis (UC). 
     
     
         3 . The method of  claim 1 , wherein said NGBP are a lyophilized material. 
     
     
         4 . The method of  claim 1 , wherein said NGBP are administered orally. 
     
     
         5 . The method of  claim 1 , wherein said patient is a human being or an animal. 
     
     
         6 . The method of  claim 5 , wherein said animal is an animal raised for food. 
     
     
         7 . The method of  claim 5 , wherein said animal is a pet animal. 
     
     
         8 . The method of  claim 1 , wherein said NGBP is added to or mixed with the feed of said animal. 
     
     
         9 . The method of  claim 1 , wherein said NGBP is added to or mixed with the drink of said animal. 
     
     
         10 . An animal feed supplement for improving health and/or meat production of an animal compromising Next Generation Bioengineered Probiotics (NGBP), wherein said NGBP comprises a bioengineered bacteria  Lactobacillus casei  ( L. casei ) expressing  Listeria  adhesion protein (LAP) having the sequence of SEQ ID NO:1 or SEQ ID NO:2. 
     
     
         11 . The animal feed supplement of  claim 10 , wherein said animal is selected from the group consisting of pig, sheep, goat, chicken, turkey, cat, dog, and cattle. 
     
     
         12 . The animal feed supplement of  claim 10 , wherein said animal feed supplement is lyophilized. 
     
     
         13 . The animal feed supplement of  claim 10 , wherein said animal feed supplement is added to or mixed together with the feed of said animal. 
     
     
         14 . The animal feed supplement of  claim 10 , wherein said animal feed supplement is added to or mixed together with the drink of said animal. 
     
     
         15 . An animal feed product comprising the animal feed supplement of  claim 10 .

Join the waitlist — get patent alerts

Track US2021386819A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.